BioMarin Pharmaceutical announced that its Board of Directors has appointed Ian T. Clark as Chair of the Board, subject to his election at the company’s Annual Meeting of Stockholders on June 2, 2026. Clark will succeed Richard A. Meier, who is retiring after two decades on the Board. The transition will take effect immediately following the Annual Meeting.
Clark joined BioMarin’s Board in 2025 and brings extensive governance and executive leadership experience across the global biopharmaceutical sector. He previously served as Chief Executive Officer of Genentech and was a member of its Board of Directors from 2010 to 2016. His board experience includes roles as lead independent director and chair at multiple public biopharmaceutical companies.
Meier joined BioMarin’s Board in 2006 and played a central role in the company’s development over nearly 20 years. He served as Lead Independent Director before being named Chair in 2023. During his tenure, the company improved profitability, expanded non-GAAP operating margins, delivered earnings-per-share growth, and generated substantial cash flow.
Alexander Hardy, President and Chief Executive Officer of BioMarin, highlighted the significance of the leadership transition as the company continues to execute its long-term strategy and global expansion in rare disease treatments.
Founded in 1997 and headquartered in San Rafael, California, BioMarin is a global biotechnology company focused on developing therapies for genetically defined conditions. The company operates in approximately 80 countries and maintains a portfolio of commercial therapies alongside a robust clinical and preclinical pipeline.
KEY QUOTES:
“I am excited to step into this role as BioMarin enters its next phase of growth as a leading rare disease company operating at scale in 80 countries. With two recent acquisitions, BioMarin has the potential to unlock significant value for all stakeholders: employees, shareholders and, most importantly, patients.”
Ian T. Clark, Incoming Chair, BioMarin Pharmaceutical Inc.
“BioMarin enters this next chapter with excellent leadership, strategic clarity and a strong foundation for continued success. The company is well positioned to build on this momentum in the years ahead. It has been an honor to serve on BioMarin’s Board over the past two decades and I am pleased to hand the reins to Ian.”
Richard A. Meier, Outgoing Chair, BioMarin Pharmaceutical Inc.
“Randy has helped guide BioMarin through a period of meaningful growth and transformation, and we are grateful for his leadership and service. I am pleased to welcome Ian to his new role. Ian brings substantial board and executive experience, and I look forward to partnering with him as we continue executing our strategy for patients around the world.”
Alexander Hardy, President and Chief Executive Officer, BioMarin Pharmaceutical
